Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine

Autor: Stéphane Culine, Yann Neuzillet, Jean-Jacques Patard
Přispěvatelé: Service d'urologie, Hôpital Foch [Suresnes], Service d'urologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), De Villemeur, Hervé
Rok vydání: 2009
Předmět:
Oncology
medicine.medical_specialty
Urology
medicine.medical_treatment
030232 urology & nephrology
MEDLINE
[SDV.CAN]Life Sciences [q-bio]/Cancer
urologic and male genital diseases
[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
MESH: Prognosis
03 medical and health sciences
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
Renal cell carcinoma
Internal medicine
Overall survival
Carcinoma
Humans
Medicine
MESH: Models
Theoretical
Carcinoma
Renal Cell
Prognostic models
MESH: Humans
Medical treatment
business.industry
MESH: Carcinoma
Renal Cell
Immunotherapy
Models
Theoretical
Prognosis
medicine.disease
[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
Kidney Neoplasms
3. Good health
030220 oncology & carcinogenesis
MESH: Kidney Neoplasms
business
Risk assessment
Zdroj: International Journal of Urology
International Journal of Urology, Wiley, 2009, 16 (11), pp.855-61. ⟨10.1111/j.1442-2042.2009.02365.x⟩
International Journal of Urology, 2009, 16 (11), pp.855-61. ⟨10.1111/j.1442-2042.2009.02365.x⟩
ISSN: 1442-2042
0919-8172
DOI: 10.1111/j.1442-2042.2009.02365.x
Popis: International audience; Prognostic factors in the setting of treated metastatic renal cell carcinoma (mRCC) can theoretically predict drug response, progression-free survival or overall survival. These factors are potentially useful for informing patients and for tailoring medical treatment according to risk assessment. Prognostic factors were well defined in the era of immunotherapy. Since 2006, tyrosine kinase inhibitors and anti-angiogenic drugs have revolutionized the treatment of mRCC by improving progression-free survival and overall survival. Physicians now need new predictive tools adapted to targeted therapies. The aim of our study was to review the current knowledge about prognostic factors in mRCC by focusing on anatomical, clinical, biological, histological, radiological and molecular parameters. The most recent integrated prognostic models will be reviewed as well.
Databáze: OpenAIRE
Externí odkaz: